Yashima K, Piatyszek M A, Saboorian H M, Virmani A K, Brown D, Shay J W, Gazdar A F
Hamon Centre for Therapeutic Oncology Research, UT Southwestern Medical Centre, Dallas 75235-8593, USA.
J Clin Pathol. 1997 Feb;50(2):110-7. doi: 10.1136/jcp.50.2.110.
AIMS/BACKGROUND: Telomerase, an enzyme associated with cellular immortality, is expressed by most malignant tumours, but is inactive in normal somatic cells except for male germ cells and proliferating stem cells. Thus, the measurement of telomerase activity in tissue samples may provide useful diagnostic and prognostic information. The aim of this study was to determine whether telomerase expression is useful for the detection of occult malignant cells in lymph nodes.
Telomerase activity was compared with histological findings in 123 surgically removed lymph nodes submitted for routine or frozen section diagnosis. Telomerase activity was measured using a modified, semi-quantitative PCR-based telomeric repeat amplification protocol (TRAP). The assay was adapted for single 5 microns OCT embedded cryostat sections. In either fresh tissues or cryostat sections, normalised activity was linear when compared with protein concentration. Furthermore, using an in situ hybridisation method, the human telomerase RNA (hTR) component was measured in a subset of negative and positive nodes.
Most (96%) of the 97 histologically negative nodes expressed low levels of activity (mean value of positive samples = 3.0 units/microgram protein) which may be derived from activated lymphocytes that express telomerase activity. All 26 malignant nodes (17 metastases, nine lymphomas) expressed telomerase (mean value = 17.8 units/microgram protein). The rank order levels between the two groups differed significantly (p = 0.0002). In situ results showed clearly that the hTR was expressed relatively highly in metastatic cancer cells and at lower levels in germinal centres of secondary follicles.
Although expression of telomerase by activated lymphocytes may limit its usefulness, measurement of enzyme activity combined with detection of hTR using in situ hybridisation may assist in the histopathological diagnosis of lymph nodes.
目的/背景:端粒酶是一种与细胞永生化相关的酶,大多数恶性肿瘤都有表达,但在正常体细胞中除了雄性生殖细胞和增殖的干细胞外均无活性。因此,检测组织样本中端粒酶活性可能提供有用的诊断和预后信息。本研究的目的是确定端粒酶表达是否有助于检测淋巴结中的隐匿性恶性细胞。
将123个手术切除的淋巴结的端粒酶活性与组织学结果进行比较,这些淋巴结用于常规或冷冻切片诊断。使用改良的基于半定量聚合酶链反应的端粒重复序列扩增方案(TRAP)测量端粒酶活性。该检测方法适用于单个5微米的OCT包埋冰冻切片。在新鲜组织或冰冻切片中,与蛋白质浓度相比,标准化活性呈线性关系。此外,使用原位杂交方法,在一部分阴性和阳性淋巴结中检测人端粒酶RNA(hTR)成分。
97个组织学阴性的淋巴结中,大多数(96%)表达低水平的活性(阳性样本的平均值=3.0单位/微克蛋白质),这可能来自表达端粒酶活性的活化淋巴细胞。所有26个恶性淋巴结(17个转移瘤,9个淋巴瘤)均表达端粒酶(平均值=17.8单位/微克蛋白质)。两组之间的活性水平排序差异显著(p=0.0002)。原位结果清楚地表明,hTR在转移癌细胞中相对高表达,在次级滤泡生发中心中表达较低。
虽然活化淋巴细胞表达端粒酶可能会限制其用途,但测量酶活性并结合使用原位杂交检测hTR可能有助于淋巴结的组织病理学诊断。